{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T16:34:18Z","timestamp":1785861258426,"version":"3.56.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1097\/01.mou.0000240310.70582.ce","type":"journal-article","created":{"date-parts":[[2006,8,10]],"date-time":"2006-08-10T04:23:49Z","timestamp":1155183829000},"page":"361-366","source":"Crossref","is-referenced-by-count":16,"title":["Intravesical gemcitabine: an update of clinical results"],"prefix":"10.1097","volume":"16","author":[{"given":"Kees","family":"Hendricksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Alfred","family":"Witjes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"R2-12-20210206","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"R3-12-20210206","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"R4-12-20210206","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1464-410X.1998.00720.x","article-title":"Bacille Calmette\u2013Guerin in superficial transitional cell carcinoma","volume":"82","author":"Mungan","year":"1998","journal-title":"Br J Urol"},{"key":"R5-12-20210206","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette\u2013Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"R6-12-20210206","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1200\/JCO.1997.15.11.3394","article-title":"Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer","volume":"15","author":"Stadler","year":"1997","journal-title":"J Clin Oncol"},{"key":"R7-12-20210206","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","article-title":"A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer","volume":"34","author":"Lorusso","year":"1998","journal-title":"Eur J Cancer"},{"key":"R8-12-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","article-title":"A phase I clinical, plasma, and cellular pharmacology study of gemcitabine","volume":"9","author":"Abbruzzese","year":"1991","journal-title":"J Clin Oncol"},{"key":"R9-12-20210206","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001813-200207000-00002","article-title":"Selective cytotoxicity of gemcitabine in bladder cancer cell lines","volume":"13","author":"Kilani","year":"2002","journal-title":"Anticancer Drugs"},{"issue":"Suppl","key":"R10-12-20210206","first-page":"508","article-title":"Studies on gemcitabine as an intravesical agent for superficial bladder cancer","volume":"169","author":"O'Donnell","year":"2003","journal-title":"J Urol"},{"key":"R11-12-20210206","first-page":"2629","article-title":"Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs","volume":"5","author":"Cozzi","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R12-12-20210206","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.1999.17.7.2190","article-title":"Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with nonsmall-cell lung cancer","volume":"17","author":"Kroep","year":"1999","journal-title":"J Clin Oncol"},{"key":"R13-12-20210206","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0302-2838(03)00372-5","article-title":"Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs","volume":"44","author":"Witjes","year":"2003","journal-title":"Eur Urol"},{"key":"R14-12-20210206","first-page":"1145","article-title":"Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder","volume":"11","author":"Matera","year":"2004","journal-title":"Oncol Rep"},{"key":"R15-12-20210206","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.urology.2004.05.035","article-title":"Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer","volume":"64","author":"Nativ","year":"2004","journal-title":"Urology"},{"key":"R16-12-20210206","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","article-title":"Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer","volume":"174","author":"Brocks","year":"2005","journal-title":"J Urol"},{"key":"R17-12-20210206","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2002.02.066","article-title":"Phase I trial of intravesical gemcitabine in bacillus Calmette\u2013Guerin-refractory transitional-cell carcinoma of the bladder","volume":"20","author":"Dalbagni","year":"2002","journal-title":"J Clin Oncol"},{"key":"R18-12-20210206","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2003.09.028","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study","volume":"21","author":"Laufer","year":"2003","journal-title":"J Clin Oncol"},{"key":"R19-12-20210206","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.eururo.2003.09.014","article-title":"Intravesical gemcitabine: a phase 1 and pharmacokinetic study","volume":"45","author":"Witjes","year":"2004","journal-title":"Eur Urol"},{"key":"R20-12-20210206","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1464-410X.2003.04656.x","article-title":"Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation","volume":"93","author":"De Berardinis","year":"2004","journal-title":"BJU Int"},{"key":"R21-12-20210206","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.ju.0000131770.14409.7f","article-title":"Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer","volume":"172","author":"Palou","year":"2004","journal-title":"J Urol"},{"key":"R22-12-20210206","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1046\/j.1464-410X.1996.09002.x","article-title":"Phase II trials in Ta, T1 bladder cancer. The marker tumor concept","volume":"77","author":"Van der Meijden","year":"1996","journal-title":"Br J Urol"},{"key":"R23-12-20210206","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.eururo.2004.05.001","article-title":"Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC)","volume":"46","author":"Gontero","year":"2004","journal-title":"Eur Urol"},{"key":"R24-12-20210206","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2004.08.027","article-title":"Gemcitabine in intravesical treatment of Ta\u2013T1 transitional cell carcinoma of bladder: phase I\u2013II study on marker lesions","volume":"65","author":"Serretta","year":"2005","journal-title":"Urology"},{"key":"R25-12-20210206","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.urology.2005.03.084","article-title":"Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent stage Ta urothelial cell carcinoma of the bladder","volume":"66","author":"Gardmark","year":"2005","journal-title":"Urology"},{"key":"R26-12-20210206","first-page":"2381","article-title":"Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability","volume":"25","author":"Campodonico","year":"2005","journal-title":"Anticancer Res"},{"key":"R27-12-20210206","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00005392-200102000-00011","article-title":"The ablative effect of quarter dose bacillus Calmette\u2013Guerin on a papillary marker lesion of the bladder","volume":"165","author":"Mack","year":"2001","journal-title":"J Urol"},{"key":"R28-12-20210206","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1159\/000473784","article-title":"Chemoresection in Ta\u2013T1 bladder cancer. Members of the EORTC Genito-Urinary Group","volume":"29","author":"Bono","year":"1996","journal-title":"Eur Urol"},{"key":"R29-12-20210206","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1159\/000052521","article-title":"The use of valrubicin for the chemoresection of superficial bladder cancer \u2013 a marker lesion study","volume":"39","author":"Newling","year":"2001","journal-title":"Eur Urol"},{"key":"R30-12-20210206","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.urology.2005.04.062","article-title":"Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a phase II prospective multicenter study","volume":"66","author":"Bartoletti","year":"2005","journal-title":"Urology"},{"key":"R31-12-20210206","first-page":"2493","article-title":"Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study","volume":"25","author":"Mattioli","year":"2005","journal-title":"Anticancer Res"},{"key":"R32-12-20210206","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"R33-12-20210206","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000089164","article-title":"Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette\u2013Guerin therapy","volume":"75","author":"Bassi","year":"2005","journal-title":"Urol Int"}],"container-title":["Current Opinion in Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00124743-200608001-00059","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:41:10Z","timestamp":1785858070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00042307-200609000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006]]}},"URL":"https:\/\/doi.org\/10.1097\/01.mou.0000240310.70582.ce","relation":{},"ISSN":["0963-0643"],"issn-type":[{"value":"0963-0643","type":"print"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}